Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Revvity, Inc. Common Stock (NY:RVTY)

104.08 -1.72 (-1.63%)
Streaming Delayed Price Updated: 3:01 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Revvity, Inc. Common Stock

< Previous 1 2 3 4 Next >
Stocks That Hit 52-Week Lows On Monday
  Monday's session saw 175 companies set new 52-week lows. 
Via Benzinga
Revvity Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries
From Revvity
Via Business Wire
Analyst Ratings for Revvity
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 225 companies set new 52-week lows. 
Via Benzinga
Revvity to Present at Upcoming September Investor Conferences
From Revvity
Via Business Wire
Revvity Announces Financial Results for the Second Quarter of 2023
From Revvity
Via Business Wire
Revvity Board Declares Quarterly Dividend
From Revvity
Via Business Wire
Revvity Accelerates NGS Library Prep with Introduction of New Fontus Automated Liquid Handling Workstation at 2023 AACC
From Revvity
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2023
Via Benzinga
Revvity to Hold Earnings Call on Tuesday, August 1, 2023
From Revvity
Via Business Wire
Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research
From Revvity
Via Business Wire
Abcam Downgrade: Analyst Trims Expectations Amid Activist Investor Engagement and Potential Bid Anticipation
RBC Capital Markets has downgraded Abcam PLC (NASDAQ: ABCM) from Outperform to Sector Perform with a price target of $22,  
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 35 stocks hit new 52-week lows. 
Via Benzinga
Revvity Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development
From Revvity
Via Business Wire
Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with New Automated IIFT System
From Revvity
Via Business Wire
Revvity to Present at Goldman Sachs Global Healthcare Conference
From Revvity
Via Business Wire
Revvity Announces New License Agreement for Next-Generation Base Editing Technology
From Revvity
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.